These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 15951303

  • 1. Rituximab monotherapy for splenic marginal zone lymphoma.
    Bennett M, Sharma K, Yegena S, Gavish I, Dave HP, Schechter GP.
    Haematologica; 2005 Jun; 90(6):856-8. PubMed ID: 15951303
    [Abstract] [Full Text] [Related]

  • 2. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
    Bennett M, Schechter GP.
    Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
    [Abstract] [Full Text] [Related]

  • 3. Re: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.
    Bennett M, Yegena S, Dave HP, Schechter GP.
    Hematol Oncol; 2008 Jun; 26(2):114. PubMed ID: 18271062
    [No Abstract] [Full Text] [Related]

  • 4. [Splenic marginal zone lymphoma associated with autoimmune hemolytic anemia treated with splenectomy and rituximab].
    Miztani M, Noda T, Umino A, Tanigawa M, Taniguchi M, Tamaki S, Tsuji K.
    Rinsho Ketsueki; 2007 Nov; 48(11):1489-91. PubMed ID: 18080507
    [Abstract] [Full Text] [Related]

  • 5. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W.
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [Abstract] [Full Text] [Related]

  • 6. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 7. Radiotherapy for low-grade gastric marginal zone lymphoma: a retrospective study.
    Lin ML, Wirth A, Chao M, Milner AD, DiIulio J, MacManus M, Seymour JF.
    Intern Med J; 2007 Mar; 37(3):172-80. PubMed ID: 17316336
    [Abstract] [Full Text] [Related]

  • 8. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, Kentos A, Pierre P, Boulet D, Bries G, Lê PQ, Janssens A, Delannoy A.
    J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
    [Abstract] [Full Text] [Related]

  • 9. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
    Morales AV, Advani R, Horwitz SM, Riaz N, Reddy S, Hoppe RT, Kim YH.
    J Am Acad Dermatol; 2008 Dec; 59(6):953-7. PubMed ID: 18817999
    [Abstract] [Full Text] [Related]

  • 10. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
    Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA.
    J Clin Oncol; 2006 Aug 20; 24(24):3880-6. PubMed ID: 16864854
    [Abstract] [Full Text] [Related]

  • 11. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
    Xia ZJ, Wang FH, Huang HQ, Luo HY, Li YH, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr 20; 25(4):490-4. PubMed ID: 16613687
    [Abstract] [Full Text] [Related]

  • 12. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group).
    Haematologica; 2008 Dec 20; 93(12):1829-36. PubMed ID: 18945747
    [Abstract] [Full Text] [Related]

  • 13. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
    Kyrtsonis MC, Siakantaris MP, Kalpadakis C, Dimopoulou MN, Vassilakopoulos TP, Kontopidou FN, Antoniou C, Korkolopoulou P, Panayiotidis P, Pangalis GA.
    Eur J Haematol; 2006 Oct 20; 77(4):300-3. PubMed ID: 16856917
    [Abstract] [Full Text] [Related]

  • 14. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
    Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR, Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP.
    Ann Hematol; 2006 Jun 20; 85(6):400-6. PubMed ID: 16550390
    [Abstract] [Full Text] [Related]

  • 15. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
    Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM.
    J Clin Oncol; 2005 Aug 01; 23(22):5044-51. PubMed ID: 15955901
    [Abstract] [Full Text] [Related]

  • 16. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
    de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL.
    J Clin Oncol; 2009 Oct 20; 27(30):5023-30. PubMed ID: 19770386
    [Abstract] [Full Text] [Related]

  • 17. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
    Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA.
    Cancer; 2005 Oct 15; 104(8):1661-7. PubMed ID: 16149091
    [Abstract] [Full Text] [Related]

  • 18. [Extranodal marginal zone lymphoma of the ocular adnexa].
    Møller A, Specht L, Toft PB, Sjø LD.
    Ugeskr Laeger; 2008 Nov 03; 170(45):3660-3. PubMed ID: 18986616
    [Abstract] [Full Text] [Related]

  • 19. Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma.
    Somer BG, Tsai DE, Downs L, Weinstein B, Schuster SJ, American College of Rheumatology ad hoc Committee on Immunologic Testing Guidelines.
    Arthritis Rheum; 2003 Jun 15; 49(3):394-8. PubMed ID: 12794796
    [No Abstract] [Full Text] [Related]

  • 20. Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience.
    Biswas G, Parikh PM, Nair R, Bhagwat R, Bakshi A, Prabhash K, Vora A, Gupta S, Pai VR, Menon H, Sastry PS.
    J Assoc Physicians India; 2006 Jan 15; 54():29-33. PubMed ID: 16649735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.